

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(formerly known as ASIA PACIFIC SILK ROAD INVESTMENT COMPANY LIMITED 亞太絲路投資有限公司)

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that on 8 April 2021, the Company entered into a memorandum of understanding (the “**MOU**”) with Mirai Medical Service Co., Ltd. (未來メテikalサービス株式会社) (“**Mirai Medical**”) in relation to the proposed acquisition by the Company of the partial interest in Mirai Medical (the “**Potential Acquisition**”).

TERM OF COOPERATION

Both parties shall negotiate amicably and agreed to enter into a legally-binding formal agreement in relation to the Potential Acquisition within 90 days after the date of the MOU or such other date as agreed by both parties (the “**Exclusive Period**”). The parties further agreed not to negotiate or enter into any agreement with any third party in relation to the Potential Acquisition or any transaction or cooperation of a similar nature before the expiry of the Exclusive Period.

INFORMATION ON MIRAI MEDICAL

Incorporated in Japan in 2010 as a company with limited liability, Mirai Medical specialises in the investment in, and the operation and management of, regenerative medicine and concentrates on the establishment of a healthcare industry platform with a focus on regenerative medical care. Since its foundation, Mirai Medical has gradually formed a business structure with regenerative medicine as the main body, comprising five major synergic segments, namely cell culture, clinical application, product research and development, medical services, and remote diagnosis and treatment, based on the study, development and application of regenerative medicine.

REASONS FOR AND BENEFITS OF THE MOU

The Board believes that the Potential Acquisition will further refine the global layout of the Group's longevity science business, thereby bringing stable and sustainable revenue growth to the Group in the long run.

Shareholders and potential investors of the Company should note that the Potential Acquisition may or may not proceed. If the transactions contemplated under the MOU materialise, the Company will make further announcement as appropriate pursuant to the Listing Rules. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 8 April 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yeung Siu Keung
Ms. Cao Xie Qiong

Non-executive Directors

Ms. Yu Yang
Ms. Choi Ngai Wah

Independent non-executive Directors

Ms. Ho Man Wai
Ms. Wang Weixia
Mr. Mak Ping Leung
(alias: Mr. Mak Wah Cheung)
Mr. To Langa Samuelson

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.